

# Evangelos N Liberopoulos

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5823354/evangelos-n-liberopoulos-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

102  
papers

2,431  
citations

21  
h-index

47  
g-index

109  
ext. papers

2,940  
ext. citations

3.3  
avg, IF

5.05  
L-index

#	Paper	IF	Citations
102	Association between lipoprotein(a) concentrations and atherosclerotic cardiovascular disease risk in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH.. <i>Endocrine</i> , <b>2022</b> , 1	4	0
101	A Horse, a Jockey, and a Therapeutic Dilemma: Choosing the Best Option for a Patient with Diabetes and Coronary Artery Disease.. <i>American Journal of Cardiovascular Drugs</i> , <b>2022</b> , 1	4	0
100	Oxidized phospholipids and lipoprotein(a): An update. <i>European Journal of Clinical Investigation</i> , <b>2021</b> , e13710	4.6	1
99	Anakinra in COVID-19: A step closer to the cure. <i>European Journal of Internal Medicine</i> , <b>2021</b> ,	3.9	2
98	LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments. <i>International Journal of Cardiology</i> , <b>2021</b> , 345, 119-124	3.2	2
97	Lipoprotein apheresis: a Hellenic consensus on its clinical use. <i>Hellenic Journal of Cardiology</i> , <b>2021</b> , 62, 460-462	2.1	1
96	Recommendations for lipid modification in patients with ischemic stroke or transient ischemic attack: A clinical guide by the Hellenic Stroke Organization and the Hellenic Atherosclerosis Society. <i>International Journal of Stroke</i> , <b>2021</b> , 16, 738-750	6.3	2
95	AuthorsSRReply to: Do All Gliflozins Reduce Stroke in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function?. <i>Journal of Stroke and Cerebrovascular Diseases</i> , <b>2021</b> , 30, 105810	2.8	
94	Lipoprotein(a): A Concealed Precursor of Increased Cardiovascular Risk? A Real-World Regional Lipid Clinic Experience. <i>Archives of Medical Research</i> , <b>2021</b> , 52, 397-404	6.6	2
93	Sodium-Glucose Cotransporter-2 Inhibitors and Protection Against stroke in Patients with type 2 Diabetes and Impaired Renal Function: A Systematic Review and Meta-Analysis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , <b>2021</b> , 30, 105708	2.8	4
92	Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a Systematic review and meta-analysis. <i>Rheumatology</i> , <b>2021</b> , 60, 5527-5537	3.9	14
91	Assessing forgetfulness and polypharmacy and their impact on health-related quality of life among patients with hypertension and dyslipidemia in Greece during the COVID-19 pandemic. <i>Quality of Life Research</i> , <b>2021</b> , 1	3.7	0
90	Sodium-glucose cotransporter inhibitors may reduce the risk of pneumonia: an updated meta-analysis of cardiovascular outcome trials. <i>Diabetology International</i> , <b>2021</b> , 1-5	2.3	0
89	Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019?. <i>Medical Hypotheses</i> , <b>2021</b> , 146, 110452	3.8	13
88	Sinus Bradycardia Associated with Remdesivir Treatment in COVID-19: A Case Report and Literature Review. <i>Journal of Cardiovascular Development and Disease</i> , <b>2021</b> , 8,	4.2	18
87	Could Dapagliflozin Attenuate COVID-19 Progression in High-Risk Patients With or Without Diabetes? Behind DARE-19 Concept. <i>Journal of Cardiovascular Pharmacology</i> , <b>2021</b> , 78, e12-e19	3.1	2
86	Bradycardia and coronavirus disease 2019: What is behind?. <i>Clinical Cardiology</i> , <b>2021</b> , 44, 1187	3.3	

85	Prevalence of Non-coronary Heart Disease in Patients with Familial Hypercholesterolemia: An Analysis from the HELLAS-FH. <i>Current Pharmaceutical Design</i> , <b>2021</b> , 27, 2537-2544	3.3	
84	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Lancet, The</i> , <b>2021</b> , 398, 1713-1725	4.0	14
83	Achieving low-density lipoprotein cholesterol targets as assessed by different methods in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH registry. <i>Lipids in Health and Disease</i> , <b>2020</b> , 19, 114	4.4	2
82	COVID-19 and diabetes: What does the clinician need to know?. <i>Primary Care Diabetes</i> , <b>2020</b> , 14, 558-563	3.4	23
81	Metabolically healthy obesity and risk of incident type 2 diabetes in 1077 statin-treated individuals: A six-year retrospective study. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> , 27, 2341-2344	3.9	3
80	Canagliflozin and Amputation Risk: Evidence So Far. <i>International Journal of Lower Extremity Wounds</i> , <b>2020</b> , 19, 21-26	1.6	8
79	Author's Reply. <i>Journal of Cardiology</i> , <b>2020</b> , 75, 217	3	
78	PCSK9 inhibitors in clinical practice: Novel directions and new experiences. <i>Hellenic Journal of Cardiology</i> , <b>2020</b> , 61, 241-245	2.1	7
77	Incidence of diabetes according to metabolic and weight status in postmenopausal women treated with statins: a 6-year study. <i>Menopause</i> , <b>2020</b> , 27, 1196	2.5	1
76	Very high-risk familial hypercholesterolaemia patients in real life: The remaining gap in achieving the current LDL-C targets despite the use of PCSK9 inhibitors. <i>Atherosclerosis</i> , <b>2020</b> , 309, 67-69	3.1	5
75	Safety Evaluation of Lipoic Acid Supplementation: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Studies. <i>Antioxidants</i> , <b>2020</b> , 9,	7.1	16
74	Diet and Cardiovascular Disease Risk Among Individuals with Familial Hypercholesterolemia: Systematic Review and Meta-Analysis. <i>Nutrients</i> , <b>2020</b> , 12,	6.7	11
73	Vitamin D status and cardiometabolic risk factors in Greek adolescents with obesity - the effect of vitamin D supplementation: a pilot study. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , <b>2020</b> , 5, e64-e71	0.9	5
72	Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> , 27, 157-165	3.9	9
71	No effect of fenugreek, bergamot and olive leaf extract on glucose homeostasis in patients with prediabetes: a randomized double-blind placebo-controlled study. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , <b>2019</b> , 4, e162-e166	0.9	2
70	Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy. <i>Case Reports in Endocrinology</i> , <b>2019</b> , 2019, 3901741	1.2	8
69	Attainment of cholesterol target values in Greece: results from the Dyslipidemia International Study II. <i>Archives of Medical Science</i> , <b>2019</b> , 15, 821-831	2.9	4
68	Atherogenic dyslipidemia increases the risk of incident diabetes in statin-treated patients with impaired fasting glucose or obesity. <i>Journal of Cardiology</i> , <b>2019</b> , 74, 290-295	3	13

67	No effect of vitamin D administration plus dietary intervention on emerging cardiovascular risk factors in patients with metabolic syndrome. <i>Journal of Nutrition &amp; Intermediary Metabolism</i> , <b>2019</b> , 16, 100093	2.8	2
66	IS MESENTERIC PANNICULITIS A SIGN FOR AUTOIMMUNE DIABETES IN ADULTS?. <i>AACE Clinical Case Reports</i> , <b>2019</b> , 5, e181-e183	0.7	
65	Long-Term Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Reduces Arterial FDG Uptake. <i>JACC: Cardiovascular Imaging</i> , <b>2019</b> , 12, 2573-2574	8.4	6
64	Bridging the treatment gap in patients at extreme cardiovascular risk: Evidence from a lipid clinic. <i>Atherosclerosis</i> , <b>2019</b> , 281, 216-218	3.1	0
63	Effect of combined vitamin D administration plus dietary intervention on oxidative stress markers in patients with metabolic syndrome: A pilot randomized study. <i>Clinical Nutrition ESPEN</i> , <b>2019</b> , 29, 198-202	1.3	6
62	Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor use in the management of resistant hypercholesterolemia induced by mitotane treatment for adrenocortical cancer. <i>Journal of Clinical Lipidology</i> , <b>2018</b> , 12, 826-829	4.9	4
61	Uric acid and incident chronic kidney disease in dyslipidemic individuals. <i>Current Medical Research and Opinion</i> , <b>2018</b> , 34, 1193-1199	2.5	11
60	Clinical pharmacology of glucagon-like peptide-1 receptor agonists. <i>Hormones</i> , <b>2018</b> , 17, 333-350	3.1	26
59	Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications. <i>Current Medicinal Chemistry</i> , <b>2018</b> , 25, 1549-1566	4.3	9
58	Prevalence, Identification, and Scouting for Familial Hypercholesterolaemia Including Registries. <i>Current Pharmaceutical Design</i> , <b>2018</b> , 24, 3605-3615	3.3	4
57	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Atherosclerosis</i> , <b>2018</b> , 277, 234-255	3.1	93
56	Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). <i>Atherosclerosis</i> , <b>2018</b> , 277, 308-313	3.1	15
55	The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. <i>Metabolism: Clinical and Experimental</i> , <b>2017</b> , 71, 17-32	12.7	152
54	Lipid testing in infectious diseases: possible role in diagnosis and prognosis. <i>Infection</i> , <b>2017</b> , 45, 575-588	5.8	28
53	The CHADS and CHADS-VASc scores predict atrial fibrillation in dyslipidemic individuals: Role of incorporating low high-density lipoprotein cholesterol levels. <i>International Journal of Cardiology</i> , <b>2017</b> , 241, 194-199	3.2	13
52	No effect of vitamin D supplementation on cardiovascular risk factors in subjects with metabolic syndrome: a pilot randomised study. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , <b>2017</b> , 2, e52-e60	0.9	15
51	An insight into familial hypercholesterolemia in Greece: rationale and design of the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). <i>Hormones</i> , <b>2017</b> , 16, 306-312	3.1	6
50	Statin escape phenomenon: Fact or fiction?. <i>World Journal of Experimental Medicine</i> , <b>2017</b> , 7, 25-30	0.4	1

49	Effects of increased body weight and short-term weight loss on serum PCSK9 levels - a prospective pilot study. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , <b>2017</b> , 2, e46-e51	0.9	9
48	Low high-density lipoprotein cholesterol levels improve the performance of the CHADS2 and CHA2DS2-VASc scores for the prediction of new-onset atrial fibrillation. <i>International Journal of Cardiology</i> , <b>2017</b> , 247, 18	3.2	1
47	An insight into familial hypercholesterolemia in Greece: rationale and design of the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). <i>Hormones</i> , <b>2017</b> , 16, 200-204	3.1	2
46	High triglyceride levels alter the correlation of apolipoprotein B with low- and non-high-density lipoprotein cholesterol mostly in individuals with diabetes or metabolic syndrome. <i>Atherosclerosis</i> , <b>2016</b> , 247, 58-63	3.1	16
45	Statin therapy with or without ezetimibe and the progression to diabetes. <i>Journal of Clinical Lipidology</i> , <b>2016</b> , 10, 306-13	4.9	29
44	Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. <i>Hormones</i> , <b>2016</b> , 15, 8-14	3.1	21
43	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. <i>Atherosclerosis Supplements</i> , <b>2016</b> , 22, 1-32	1.7	60
42	A contemporary cross-sectional study on dyslipidemia management, cardiovascular risk status, and patients' quality of life in Greece: The CHALLENGE study. <i>International Journal of Cardiology</i> , <b>2016</b> , 217, 183-9	3.2	5
41	Lipid target achievement among patients with very high and high cardiovascular risk in a lipid clinic. <i>Angiology</i> , <b>2015</b> , 66, 346-53	2.1	20
40	Familial hypercholesterolaemia: A global call to arms. <i>Atherosclerosis</i> , <b>2015</b> , 243, 257-9	3.1	123
39	Combining rosuvastatin with angiotensin-receptor blockers of different PPAR $\alpha$ activating capacity: effects on high-density lipoprotein subfractions and associated enzymes. <i>Angiology</i> , <b>2015</b> , 66, 36-42	2.1	5
38	How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic. <i>Current Medical Research and Opinion</i> , <b>2015</b> , 31, 221-8	2.5	16
37	Dapagliflozin in patients with type 2 diabetes mellitus. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , <b>2015</b> , 6, 29-41	4.5	18
36	Attainment of multifactorial treatment targets among the elderly in a lipid clinic. <i>Journal of Geriatric Cardiology</i> , <b>2015</b> , 12, 239-45	1.7	4
35	Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia. <i>Cardiovascular Therapeutics</i> , <b>2014</b> , 32, 139-46	3.3	14
34	Visceral leishmaniasis is associated with marked changes in serum lipid profile. <i>European Journal of Clinical Investigation</i> , <b>2014</b> , 44, 719-27	4.6	12
33	Diabetes mellitus and electrolyte disorders. <i>World Journal of Clinical Cases</i> , <b>2014</b> , 2, 488-96	1.6	144
32	No association between high-density lipoprotein levels and ventricular repolarization indexes in subjects with primary hypercholesterolemia. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>2014</b> , 74, 53-8	2	3

31	Autoimmune manifestations in patients with visceral leishmaniasis. <i>Journal of Microbiology, Immunology and Infection</i> , <b>2013</b> , 46, 302-5	8.5	20
30	Effects of manidipine plus rosuvastatin versus olmesartan plus rosuvastatin on markers of insulin resistance in patients with impaired fasting glucose, hypertension, and mixed dyslipidemia. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2013</b> , 18, 113-8	2.6	6
29	Lipid-modulating treatments for mixed dyslipidemia increase HDL-associated phospholipase A2 activity with differential effects on HDL subfractions. <i>Lipids</i> , <b>2013</b> , 48, 957-65	1.6	2
28	Spurious electrolyte disorders: a diagnostic challenge for clinicians. <i>American Journal of Nephrology</i> , <b>2013</b> , 38, 50-7	4.6	66
27	Effect of simvastatin/ezetimibe 10/10 mg versus simvastatin 40 mg on serum vitamin D levels. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2013</b> , 18, 229-33	2.6	15
26	Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial. <i>European Journal of Clinical Investigation</i> , <b>2013</b> , 43, 698-707	4.6	11
25	The effect of combining rosuvastatin with sartans of different peroxisome proliferator receptor- $\alpha$ activating capacity on plasma 8-isoprostane prostaglandin F2a levels. <i>Archives of Medical Science</i> , <b>2013</b> , 9, 172-6	2.9	10
24	New-onset extremely low levels of high-density lipoprotein cholesterol. <i>Journal of Clinical Lipidology</i> , <b>2012</b> , 6, 593-5	4.9	6
23	The relationship of vitamin D with non-traditional risk factors for cardiovascular disease in subjects with metabolic syndrome. <i>Archives of Medical Science</i> , <b>2012</b> , 8, 437-43	2.9	19
22	Prevalence and risk distribution of residual dyslipidemia in statin-treated patients in Greece. <i>Angiology</i> , <b>2012</b> , 63, 184-93	2.1	13
21	Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis. <i>Angiology</i> , <b>2012</b> , 63, 358-66	2.1	21
20	Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2012</b> , 17, 382-6	2.6	15
19	Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor- $\alpha$ activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A $\alpha$ . <i>Metabolic Syndrome and Related Disorders</i> , <b>2011</b> , 9, 217-23	2.6	3
18	Novel roles of vitamin D in disease: what is new in 2011?. <i>European Journal of Internal Medicine</i> , <b>2011</b> , 22, 355-62	3.9	77
17	"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. <i>Current Vascular Pharmacology</i> , <b>2011</b> , 9, 531-2	3.3	91
16	Hypocholesterolemia. <i>Current Vascular Pharmacology</i> , <b>2011</b> , 9, 200-12	3.3	18
15	Leptospirosis is associated with markedly increased triglycerides and small dense low-density lipoprotein and decreased high-density lipoprotein. <i>Lipids</i> , <b>2011</b> , 46, 953-60	1.6	21
14	"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. <i>Current Vascular Pharmacology</i> , <b>2011</b> , 9, 533-7	3.3	138

13	Vitamin D and metabolic syndrome: is there a link?. <i>Current Pharmaceutical Design</i> , <b>2010</b> , 16, 3417-34	3.3	29
12	Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study. <i>Clinical Therapeutics</i> , <b>2010</b> , 32, 492-505	3.5	41
11	Comparison of hemoglobin A1c and fasting glucose criteria to diagnose diabetes among people with metabolic syndrome and fasting glucose above 100 mg/dL (5.5 mmol/L). <i>Journal of Clinical Hypertension</i> , <b>2010</b> , 12, 543-8	2.3	2
10	Statin pleiotropy against renal injury. <i>Journal of the Cardiometabolic Syndrome</i> , <b>2009</b> , 4, E4-9		30
9	A patient with new-onset hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , <b>2009</b> , 3, 143-5	4.9	2
8	Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. <i>Expert Opinion on Drug Safety</i> , <b>2008</b> , 7, 717-25	4.1	53
7	Should a statin be prescribed to every patient with heart failure?. <i>Heart Failure Reviews</i> , <b>2008</b> , 13, 211-25		13
6	Multiple actions of high-density lipoprotein. <i>Current Opinion in Cardiology</i> , <b>2008</b> , 23, 370-8	2.1	154
5	Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. <i>Nephrology Dialysis Transplantation</i> , <b>2007</b> , 22, 118-27	4.3	114
4	Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, coronary heart disease, stroke, and peripheral arterial disease in a Mediterranean cohort. <i>Angiology</i> , <b>2007</b> , 58, 689-97	2.1	113
3	Effects of eprosartan on serum metabolic parameters in patients with essential hypertension. <i>Open Cardiovascular Medicine Journal</i> , <b>2007</b> , 1, 22-6	0.7	10
2	Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?. <i>Metabolism: Clinical and Experimental</i> , <b>2006</b> , 55, 1293-301	12.7	208
1	Cryoglobulinemic purpura in visceral leishmaniasis. <i>Rheumatology International</i> , <b>2005</b> , 25, 469-71	3.6	15